Inicio>>Signaling Pathways>> Others>> Lipases>>MAGL Inhibitor Compound 23

MAGL Inhibitor Compound 23

Catalog No.GC41185

MAGL Inhibitor Compound 23 es un inhibidor potente, selectivo, reversible y competitivo de MAGL, con una IC50 de 80 nM. El compuesto inhibidor de MAGL 23 exhibe efectos antiproliferativos contra las células de cÁncer de mama, colorrectal y de ovario humanos. El compuesto inhibidor de MAGL 23 bloquea MAGL en ensayos basados en células e in vivo.

Products are for research use only. Not for human use. We do not sell to patients.

MAGL Inhibitor Compound 23 Chemical Structure

Cas No.: 2324160-91-8

Tamaño Precio Disponibilidad Cantidad
5mg
52,00 $
Disponible
10mg
92,00 $
Disponible
50mg
357,00 $
Disponible
100mg
561,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MAGL inhibitor compound 23 is an inhibitor of monoacylglycerol lipase (MAGL; IC50 = 80 nM). It is selective for MAGL over cannabinoid receptor 1 (CB1), CB2, fatty acid amide hydrolase (FAAH), α/β-hydrolase domain-containing protein 6 (ABHD6), and ABHD12 (IC50s = >10 μM). MAGL inhibitor compound 23 inhibits the growth of HCT116, MDA-MB-231, Caov-3, OVCAR-3, and SKOV3 cells (IC50s = 21, 7.9, 25, 57, and 15 μM, respectively) but not MRC5 cells (IC50 = >100 μM). It increases the levels of 2-arachidonoyl glycerol in mouse brain and plasma when administered at a dose of 50 mg/kg.

Reseñas

Review for MAGL Inhibitor Compound 23

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MAGL Inhibitor Compound 23

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.